IN8bio, Inc. announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65thAmerican Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023. Details for the ASH 2023 presentation are as follows: Title: INB-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy). Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center (KUCC).

Session Name: Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III. Ten patients have been treated, completing the dose-escalation of this Phase 1 trial as of the abstract data cut off of July 14, 2023. Updated data on safety and efficacy, including CRs and durability of response will be presented in December.

The Phase 1 clinical trial (NCT03533816) is a dose-escalation trial of allogeneic derived, gamma-delta T cells from matched related donors that have been expanded and activated ex vivo and administered systemically to patients with hematologic malignedancies following hematopoietic bone marrow transplantation (HSCT). The single-institution clinical trial is currently being conducted at The University of Kansas Cancer Center. The primary endpoints of this trial are safety and tolerability, and secondary endpoints include rates of GvHD, relapse rate and overall survival.